Ipca Laboratories Ltd. — Investor Relations & Filings
Ipca Laboratories Ltd. is a vertically integrated entity focused on the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs) and finished dosage formulations. The company serves a global market, distributing products to over 120 countries. Its therapeutic portfolio covers rheumatology, antimalarials, cardiology, gastroenterology, pain management, and diabetology. Notably, it is a leading global producer of antimalarial agents such as Chloroquine and Hydroxychloroquine. Operations are supported by multiple manufacturing sites that adhere to international regulatory standards, alongside dedicated research and development centers. The company’s strategic emphasis on backward integration allows for optimized production processes and the delivery of high-quality medicinal solutions across diverse healthcare sectors.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Disclosure under SEBI Takeover Regulations | 2026-04-10 | English | |
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-08 | English | |
| Copy of Newspaper Publication | 2026-04-02 | English | |
| Trading Window | 2026-03-16 | English | |
| Analysts/Institutional Investor Meet/Con. Call Updates | 2026-02-18 | English | |
| Analysts/Institutional Investor Meet/Con. Call Updates | 2026-02-16 | English |
Browse filings by year
17 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 42201504 | Disclosure under SEBI Takeover Regulations | 2026-04-10 | English | ||
| 42185624 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-08 | English | ||
| 42168170 | Copy of Newspaper Publication | 2026-04-02 | English | ||
| 42188833 | Trading Window | 2026-03-16 | English | ||
| 42176520 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-02-18 | English | ||
| 42193964 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-02-16 | English | ||
| 42201021 | Copy of Newspaper Publication | 2026-02-16 | English | ||
| 42248926 | Outcome of Board Meeting | 2026-02-13 | English | ||
| 42254278 | General Updates | 2026-02-09 | English | ||
| 42274342 | General Updates | 2026-02-07 | English | ||
| 42284402 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-02-06 | English | ||
| 43885162 | Board Meeting — Board Meeting Intimation | 2026-01-22 | English | ||
| 43885178 | Board Meeting — Financial Results | 2026-01-22 | English | ||
| 42182149 | Updates | 2026-01-21 | English | ||
| 42222185 | Updates | 2026-01-13 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
ESSA Pharma Inc.
Develops drugs targeting the androgen receptor's N-terminal…
|
EPIX | US | Manufacturing |
|
Essex Bio-Technology Limited
Develops and manufactures biologic drugs using recombinant …
|
1061 | HK | Manufacturing |
|
Estrella Immunopharma, Inc.
Clinical-stage biopharma developing T-cell immunotherapies …
|
ESLA | US | Manufacturing |
|
Eton Pharmaceuticals, Inc.
Pharmaceutical company developing and commercializing treat…
|
ETON | US | Manufacturing |
|
EuBiologics Co., Ltd.
A biopharmaceutical company developing vaccines and offerin…
|
206650 | KR | Manufacturing |
|
Eupraxia Pharmaceuticals Inc.
Clinical-stage biotech developing targeted extended-release…
|
EPRX | CA | Manufacturing |
|
EUPRAXIA PHARMACEUTICALS INC.
Clinical-stage biotech developing locally delivered, extend…
|
EPRX | CA | Manufacturing |
|
Eureka 93 Inc.
Vertically integrated life sciences company focused on CBD …
|
— | CA | Manufacturing |
|
eureKING
A SPAC created to acquire European biomanufacturing compani…
|
KINGS | FR | Manufacturing |
|
EuroAPI
Develops and manufactures APIs and provides CDMO services f…
|
EAPI | FR | Manufacturing |
Ipca Laboratories Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/61700/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=61700 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=61700 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=61700 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 61700}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Ipca Laboratories Ltd. (id: 61700)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.